CECXG: Difference between revisions

| Watchedfields = changed

| verifiedrevid = 445373968

| routes_of_administration =

| excretion =

| molecular_weight = 381.421 g/mol

'''CECXG''' ('''3'-ethyl-LY-341,495''') is a research drug which acts as a potent and selective antagonist for the group II metabotropic glutamate receptors ([[Metabotropic glutamate receptor|mGluR_2/3]]), with reasonable selectivity for mGluR₃. While it is some five times less potent than [[LY-341,495]] at mGluR₃, it has 38x higher affinity for [[Metabotropic glutamate receptor 3|mGluR₃]] over [[Metabotropic glutamate receptor 2|mGluR₂]],<ref name="pmid9873635">{{cite journal |author=Collado I, Ezquerra J, Mazón A, Pedregal C, Yruretagoyena B, Kingston AE, Tomlinson R, Wright RA, Johnson BG, Schoepp DD |title=2,3'-disubstituted-2-(2'-carboxycyclopropyl)glycines as potent and selective antagonists of metabotropic glutamate receptors |journal=Bioorganic & Medicinal Chemistry Letters |volume=8 |issue=20 |pages=2849–54 |year=1998 |month=October |pmid=9873635 |doi=10.1016/S0960-894X(98)00510-1 |url=}}</ref> making it one of the few ligands available that is able to distinguish between these two closely related receptor subtypes.<ref>Jan Egebjerg, Povl Krogsgaard-Larsen, Arne Schousboe. Glutamate and gaba receptors and transporters: structure, function and pharmacology. pp 171-173. Taylor & Francis, 2002. ISBN 0748408819</ref><ref>{{cite doi|10.1016/S0968-0896(02)00387-5}}</ref><ref>{{cite doi|10.1016/j.jns.2006.03.018}}</ref>

{{pharm-stub}}

==References==

{{reflist}}

{{Glutamate_receptor_ligands}}

[[Category:Eli Lilly and Company]]

[[Category:Xanthenes]]